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validation of final SPACE scores included clinical validity (against Harvey-Brad-
shaw score), concurrent validity (against Treatment Satisfaction Questionnaire for
Medication –TSQM–), internal consistency reliability, test-retest reliability and
responsiveness. RESULTS: The main population included 279 patients (mean
age36, 56% female). Quality of completion was good (55-67% of patients with no
missing items). Four items were little informative and thus removed from the final
questionnaire. Eleven scores were defined: disease control, three transition scales
(non-anal symptoms, anal symptoms, quality of life), side-effects, treatment con-
venience, three expectation disconfirmation scales (efficacy, side-effects, conve-
nience), satisfaction with treatment, and motivation. Psychometric scores
matched standards for clinical validity (better perception for patients with less
severe disease), concurrent validity (e.g. correlation between SPACE satisfaction
with treatment and TSQM satisfaction scores0.59), internal consistency reliabil-
ity (Cronbach’s alphas0.67-0.93), test-retest reliability (intraclass correla-
tions0.62-0.91), and responsiveness (better perception improvement for im-
proved patients). CONCLUSIONS: The SPACE questionnaire is a valid, reliable and
responsive instrument to measure patients’ satisfaction with anti-TNF treatment
in severe Crohn’s disease.
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OBJECTIVES: Proton-pump inhibitors main action is a pronounced and long-lasting
production of gastric acid production. They have largely replaced H3/4 antagonists
in the treatment of acute peptic ulcer disease. Peptic ulcer affects 10% of population
with prevalence 2-3%. The incidence is higher in male population. Empiric treat-
ment with proton pump inhibitors provides sustained symptomatic relief in 70-
80% of patients. METHODS: Data of proton-pump inhibitors consumption within
2008-2011 were gained from Slovak Institute of Drug Control and statistically eval-
uated. Wholesalers in Slovakia are legally obliged to provide SIDC with financial
and physical units of supplied medicines. RESULTS: Financial expenditures of pan-
toprazole showed upward trend from 1.2 mil. € in 2008 to 3.1 mil. € in 2010 and then
plunged to 2.7 mil € in 2011. The costs of esomeprazole rose gradually from 42 417
€ in 2008 to 158 665 € in 2011. The consumption expressed in number of packages
increased within the followed period most remarkably by pantoprazole from 63 924
packages in 2008 to 771 197 packages in 2011. Similar increase in number of pack-
ages was observed by esomeprazole, which rocketed from 3 090 packages in 2008 to
27 650 in 2011. Continuous decline was detected by esomeprazole and lansoprazole
in both financial and physical units. CONCLUSIONS: The whole consumption of
proton-pump inhibitors decreased due to interventions of Ministry of Health in
Slovak Rebublic including categorizations and reference pricing. Treatment adjust-
ment decided by physician are also contributing factor. High utilization of panto-
prazole is caused by new medicines market release.
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OBJECTIVES: To evaluate the changes in the cost of HCV therapy after boceprevir
addition to standard therapy. The analysis is made from the third party payer perspec-
tive for one year time horizon.METHODS: Budget impact model was used combining
the HCV epidemiology data, and differences in the boceprevir efficacy in naive and
experienced patients with relapse. The cost of pharmacotherapy was calculated for
treatment naive (n191) and experienced patients (n98) alone, as well as for achiev-
ing sustained virusologycal response. Standard therapy cost alone and standard ther-
apy plus boceprevir was compared to derive the budget impact. RESULTS: Pharma-
cotherapy cost differs among subgroups of patients with heavier burden for the
experienced cirrhotic patients (36,000 Euro). Increase in the cost of pharmacotherapy
in treatment naive group is twice after boceprevir addition but efficacy is three times
higher. Addition of boceprevir to treatment naive early responder patients led to the
overall decrease in their cost of therapy to 29,000 Euro. The decrease in mean phar-
macotherapy cost of standard regime was also observed after boceprevir addition thus
influencing positively the overall treatment cost. For treatment experienced patients
the efficacy is lower but still it is twice higher than that of the standard therapy.
Achievement of sustained virusologycal response in experienced group saves approx-
imately 7,500 Euro per patient in comparison with standard therapy. CONCLUSIONS:
Addition of boceprevir to standard HCV therapy led to the overall decrease in therapy
cost mostly evident in treatment experienced patients.
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OBJECTIVES: Various treatment options exist for managing UC in the UK. Relapse-
associated treatment patterns, and the degree to which treatment options differ by
physician specialty, however, have not been studied. This study aimed to describe
common relapse-related treatment patterns for UC, both overall and by physician
specialty.METHODS:A retrospective chart review of UC patients diagnosed at least
1 year prior to the study was performed. General practitioners (GPs, 12) and gastro-
enterologists (GIs, 17) reported on treatments given to 91 patients who had expe-
rienced at least 1 flare in the past year. Treatment options (increasing dosage of
existing treatment, new oral steroid prescription, topical prescription, other pre-
scription, further investigation, and any hospitalization or surgery) were grouped
into 8 distinct treatment patterns. Descriptive statistics and the Fisher exact test
were used to assess treatment patterns by type and physician specialty, stratifying
by UC status at last assessment (remission vs. mild/moderate). RESULTS: Top
treatment patterns for UC relapse/flare included increasing the dosage of existing
medication (19% of patients), prescribing a new oral steroid (19%) or prescribing a
combination of 2 treatment options (22%). Any hospitalization or surgery was re-
ported in 7 cases (8%). Adjusting for mild/moderate UC, GIs more often prescribed
2 or 3 combinations of treatment options compared to GPs (30% and 25% vs. 11.5%
and 3.8%), and utilized any hospitalization/surgery as a treatment option (10% vs.
3.8%) and GPs were significantly more likely to report prescribing a new oral steroid
only compared to GIs (26.9% vs. 10%; p0.03). CONCLUSIONS: While a variety of
treatment options are commonly used to treat UC flares, treatment patterns dif-
fered by physician specialty, even when adjusting for disease status. Further re-
search is needed to understand how physician treatment patterns lead to different
outcomes in order to improve UC management in the UK.
MENTAL HEALTH - Clinical Outcomes Studies
PMH1
ANTAGONISTIC DRUG PRESCRIBING: CHOLINESTERASE INHIBITORS AND
ANTICHOLINERGICS
Huisman L, Dijkstra H, Vegter S
University of Groningen, Groningen, The Netherlands
OBJECTIVES: Drugs from opposing pharmacologic classes should not be combined
as this may reduce the effectiveness of one or both drugs. Physicians and pharma-
cists may however be tempted to treat adverse drug effects from one drug class
with an opposing drug class. Cholinesterase inhibitors, used for the treatment of
dementia, may cause urinary incontinence, which may in turn be treated with
anticholinergic spasmolytics. The objective of this study was to determine whether
this inappropriate prescribing cascade occurs in clinical practice. METHODS: Pre-
scription data from community pharmacies between 2000 and 2012 were re-
trieved from the IADB.nl database in The Netherlands. Patients receiving anti-
cholinergic spasmolytics were selected as cases. Each case was matched to
three controls on age and gender. A case-control design was used to determine
whether cholinesterase inhibitors preceded prescription of anticholinergic
spasmolytics. RESULTS: A total of 10,989 patients initiated treatment with an-
ticholinergic spasmolytics; these cases were matched to 32,967 controls. Pa-
tients receiving cholinesterase inhibitors in the preceding year were more likely
to receive anticholinergic spasmolytics, OR 5.6 (95% CI: 3.7-8.5). Results were not
influenced by potential confounders and did not differ significantly between
genders. Differences between cholinesterase inhibitor drugs were non-signifi-
cant, with OR ranging from 3.9 (1.4-10.4) for Galantamine to 6.6 (4.0-10.9) for
Rivastigmine. CONCLUSIONS: This matched case-control study found that pa-
tients using cholinesterase inhibitors, for treatment of dementia, were more
likely to receive anticholinergic spasmolytics to manage urinary incontinence.
Coprescription of these antagonistic drug classes constitutes illogical pharma-
cotherapy and may increase the decline in mental status of patients. Therefore,
other treatments should be preferred for these patients. The correct manage-
ment of drugs with opposing pharmacologic properties is an important aspect of
pharmaceutical care for patients with dementia.
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OBJECTIVES: To characterize patient sample, treatment patterns, and provide
1-year costs of an ongoing observational study of pediatric Attention Deficit/Hy-
peractivity Disorder (ADHD) patients in Europe. METHODS: AUTOR is a European
observational study investigating factors associated with ADHD severity changes
across a 2-year follow-up period in patients aged 6-17 that are stable responders on
their first pharmacotherapy. At baseline, patients must have taken their ADHD
medication for 3-8 months and have a Clinical Global Impression Severity score3
and Improvement score 2 compared to treatment initiation. Data were collected
at months 0, 3, 6, 9, 12, 18, and 24. UK unit costs of health & social care (PSSRU 2011)
were used for analysis. RESULTS: A total of 703 patients (Italy: 224 [32%], Romania:
196 [28%], Greece: 125 [18%], UK: 72 [10%], Slovenia: 42 [6%], Sweden: 21 [3%], The
Netherlands: 17 [2.4%], Denmark: 6 [1%]) were analyzed (98 out of 801 failed to meet
entry criteria). Patient characteristics: mean (SD) age 10.7 (2.7) years, 99% Cauca-
sian, 82% male, 76% combined ADHD subtype. Most prominent baseline comorbidi-
ties: oppositional defiant disorder (28%), anxiety (15%), dyslexia (20%), and other
learning disorders (33%). Baseline medication: Stimulants298 patients (51%
methylphenidate, 49% long-acting methylphenidate), atomoxetine393 patients,
other pharmacotherapy8 patients, drug combination4 patients. Mean (SD)
treatment duration before baseline: 4.9 (1.5) months. Mean (SD) total costs after 1
year: £7520 (7374.5), split into £3618 (4171.7) direct costs excluding treatment (48%),
£1783 (2933.6) treatment costs (24%), and £2119 (4911.2) indirect costs (28%). After 1
year, 82 patients (12%) have discontinued and 621 patients (88%) are ongoing.
CONCLUSIONS: The AUTOR sample differs from clinical trials in its higher preva-
A333V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
